Novel gyrase mutations and characterization of ciprofloxacin-resistant clinical strains of Enterococcus faecalis isolated in Poland

• Autorzy: Piekarska K , Gierczynski R. , Lawrynowicz-Paciorek M. , Kochman M. , Jagielski M.
• Języki publikacji: EN

Abstrakty

EN

The activity of ciprofloxacin, sparfloxacin and moxifloxacin was determined for 205 Enterococcus faecalis isolates from patients of five hospitals (Warsaw, Poland; collected from 2000 to 2002). Ciprofloxacin resistant and intermediate isolates were numerous (53.7%). Among them, highly resistant (MIC≥16 mg/l) isolates predominated (98%). Isolates resistant to ciprofloxacin were also resistant to sparfloxacin and moxifloxacin. The parC and gyrA QRDRs (quinolone-resistance-determining region) of 11 isolates with ciprofloxacin MICs from 1 to 256 mg/l were analysed by DNA sequencing. In ParC one kind of amino acid substitution (of Ser-85 to Ile) in 9 E. faecalis strains with MICs from 16 to 256 mg/l was observed. In GyrA Ser-84 was changed to one of four different amino acids: Arg, He, Cys or Tyr, however no association between the amino acid type and MIC value was found. The last two substitutions have not been reported to date for E. faecalis. Moreover, our results may suggest that mutations within parC and gyrA are associated with development of a high-level of ciprofloxacin resistance.

Słowa kluczowe

EN

biochemical test; Poland; mutation; sparfloxacin; enterococcal infection; human disease; isolate; moxifloxacin; Enterococcus faecalis; identification; parC gene; determination; ciprofloxacin; gyrA gene; hospital patient; resistance

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2008
• Tom: 57
• Numer: 2
• Opis fizyczny: p.121-124,ref.

Twórcy

autor

Piekarska K

• National Institute of Public Health - National Institute of Hygiene, 24 Chocimska Street, 00-791 Warsaw, Poland

autor

Gierczynski R.

autor

Lawrynowicz-Paciorek M.

autor

Kochman M.

autor

Jagielski M.

Bibliografia

• Barišić Z. and V. Punda-Polić. 2000. Antibiotic resistance among enterococcal strains isolated from clinical specimens, Internat. J. Antimicrob. Agents 16: 65-68.
• Clinical Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement M100-S16, vol.26. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania, USA.
• El Amin N., S. Jalal and B. Wretlind. 1999. Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 43: 947-949.
• Eliopoulos G.M. 1993. Increasing problems in the therapy of enterococcal infections. Eur. J. Clin. Microbiol. Infect. Dis. 6: 409-412.
• Facklam R. R, D. F. Sahm and L. M. Teixeira. 1999. Manual of Clinical Microbiology, 7th ed. ASM Press, Washington D.C.
• Gierczyński R., S. Kałużewski, A. Rakin, M. Jagielski, A. Zasada, A. Jakubczak, B. Borkowska-Opacka and W. Rastawiecki. 2004. Intriguing diversity of Bacillus anthracis in eastern Poland - the molecular echoes of the past outbreaks. FEMS Microbiol. Lett. 239: 235-240.
• Hunt C.P. 1998. The emergence of enterococci as a cause of nosocomial infection. Br. J. Biomed. Sci. 55: 149-156.
• Jonas B. M., B. E. Murray and G. M. Weinstock. 2001. Characterization of emeA, a nor A homolog and multidrug resistance efflux pump in Enterococcus faecalis. Antimicrob. Agents Chemother. 45: 3574-3579.
• Kanematsu E., T. Deguchi, M. Yasuda, T. Kawamura, Y. Nishino and Y. Kawada. 1998. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis. Antimicrob. Agents Chemother. 42: 433-435.
• Kawalec M.. Z. Pietras, E. Daniłowicz, A. Jakubczak, M. Gniadkowski, W. Hryniewicz and R.J.L. Willems. 2007. Clonal structure of Enterococcus faecalis isolated from Polish hospitals: the characterization of epidemic clones. J. Clin. Microbiol. 45: 147-153.
• Korten V., W.M. Huang and B.E. Murray. 1994. Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis. Antimicrob. Agents Chemother. 38: 2091-2094.
• Onodera Y., J. Okuda, M. Tanaka and K. Sato. 2002. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV of Enterococcus faecalis. Antimicrob. Agents Chemother. 46: 1800-1804.
• Oyamada Y., H. Ito, M. Inoue and J. Yamagishi. 2006. Topoisomerase mutations and efflux are associated with fluoroquinolone resistance in Enterococcus faecalis. J. Med. Microbiol. 55: 1395-1401.
• Schaberg D.R., W.I. Dillon, M.S. Terpenning, K.A. Robinson, S.F. Bradley and C.A. Kauffman. 1992. Increasing resistance of enterococci to ciprofloxacin. Antimicrob. Agents Chemother. 36: 2533-2535.
• Tankovic J., F. Mahjoubi, P. Courvalin, J. Duval and R. Leclercq. 1996. Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene. Antimicrob. Agents Chemother. 40: 2558-2561.
• Zaręba T. and W. Hryniewicz. 1995. Patters of antibiotic resistance among enterococcal strains isolated from clinical specimens and food in Poland. Eur. J. Clin. Microbiol. Infect. Dis. 14: 69-71.